These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23506208)

  • 41. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Vogelmeier C; Verkindre C; Cheung D; Galdiz JB; Güçlü SZ; Spangenthal S; Overend T; Henley M; Mizutani G; Zeldin RK
    Pulm Pharmacol Ther; 2010 Oct; 23(5):438-44. PubMed ID: 20416390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.
    D'Urzo A; Ferguson GT; van Noord JA; Hirata K; Martin C; Horton R; Lu Y; Banerji D; Overend T
    Respir Res; 2011 Dec; 12(1):156. PubMed ID: 22151296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
    Chapman KR; Hurst JR; Frent SM; Larbig M; Fogel R; Guerin T; Banerji D; Patalano F; Goyal P; Pfister P; Kostikas K; Wedzicha JA
    Am J Respir Crit Care Med; 2018 Aug; 198(3):329-339. PubMed ID: 29779416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
    Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
    Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ
    Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ▾Glycopyrronium for COPD.
    Drug Ther Bull; 2013 Jun; 51(6):66-8. PubMed ID: 23744364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.
    Borghardt JM; Weber B; Staab A; Kunz C; Formella S; Kloft C
    Br J Clin Pharmacol; 2016 Mar; 81(3):538-52. PubMed ID: 26348533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
    Dumitras S; Sechaud R; Drollmann A; Pal P; Vaidyanathan S; Camenisch G; Kaiser G
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):771-9. PubMed ID: 24040847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE
    Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology, toxicology and clinical safety of glycopyrrolate.
    Chabicovsky M; Winkler S; Soeberdt M; Kilic A; Masur C; Abels C
    Toxicol Appl Pharmacol; 2019 May; 370():154-169. PubMed ID: 30905688
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
    Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
    Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
    Borghardt JM; Weber B; Staab A; Kunz C; Kloft C
    Br J Clin Pharmacol; 2016 Sep; 82(3):739-53. PubMed ID: 27145733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
    Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
    Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.